Interfering PLD1-PED/PEA15 interaction using self-inhibitory peptides: An in silico study to discover novel therapeutic candidates against type 2 diabetes

Diabetes type 2 (T2D) is a very complex disorder with a large number of cases reported worldwide. There are several reported molecular targets which are being used towards drug design. In spite of extensive research efforts, there is no sure shot treatment available. One of the major reasons for thi...

Full description

Bibliographic Details
Main Authors: Mohammad Hassan Baig, Mohd Adnan Kausar, Fohad Mabood Husain, Shazi Shakil, Irfan Ahmad, Brijesh S. Yadav, Mohd Saeed
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Saudi Journal of Biological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1319562X18301955
Description
Summary:Diabetes type 2 (T2D) is a very complex disorder with a large number of cases reported worldwide. There are several reported molecular targets which are being used towards drug design. In spite of extensive research efforts, there is no sure shot treatment available. One of the major reasons for this failure or restricted success in T2D research is the identification of a major/breakthrough therapeutic target responsible for the progression of T2D. It has been well documented that one of the major causes mediating the insulin resistance is the interaction of PLD1 with PED/PEA15. Herein, we have performed in silico experiments to investigate the interaction between PLD1 with PED/PEA15. Furthermore, this study has explored pertinent molecular interactions involving the self-derived peptides. The peptides identified in this study are found to be capable of restricting the interaction of these two proteins. Accordingly, the study suggests that the “self-derived peptides” could be used as promising therapeutic candidate(s) against T2D. Keywords: Diabetes, Phospholipase D1 (PLD1), Phosphoprotein enriched in diabetes (PED/PEA15), Molecular interactions, Peptides
ISSN:1319-562X